ALACHUA, FL, United States
ALACHUA, FL, United States

Time filter

Source Type

Patent
Foundation University and Banyan Biomarkers, Inc. | Date: 2016-11-01

The present invention identifies biomarkers that are diagnostic of nerve cell injury and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.


Patent
Banyan Biomarkers, Inc. | Date: 2017-01-11

A process for diagnosing and treating a neurological condition in a subject is provided that includes assaying a biological sample of a subject for the presence of one or more biomarkers; diagnosing a neurological condition based on a ratio of one or more of the biomarkers in the sample; and administering a therapeutic to the subject to alter the ratio of one or more biomarkers. The diagnosis of numerous neurological conditions such as brain injury or multiple organ injury is provided.


An in vitro diagnostic (IVD) device is used to detect the presence of and/or severity of neural injuries or neuronal disorders in a subject. The IVD device relies on an immunoassay which identifies biomarkers that are diagnostic of neural injury and/or neuronal disorders in a biological sample, such as whole blood, plasma, serum, and/or cerebrospinal fluid (CSF). An IVD device may measure one or more of several neural specific markers in a biological sample and output the results to a machine readable format, either to a display device or to a storage device internal or external to the IVD.


Patent
Foundation University and Banyan Biomarkers, Inc. | Date: 2012-05-11

The present invention relates to an exemplary in vitro diagnostic (IVD) device used to detect the presence of and/or severity of neural injuries or neuronal disorders in a subject. The IVD device relies on an immunoassay which identifies biomarkers that are diagnostic of neural injury and/or neuronal disorders in a biological sample, such as whole blood, plasma, serum, cerebrospinal fluid (CSF). The inventive IVD device may measure one or more of several neural specific markers in a biological sample and output the results to a machine readable format wither to a display device or to a storage device internal or external to the IVD.


The present invention identifies biomarkers that are diagnostic of neural injury, neuronal disorder or neurotoxicity and is related to the discovery that proteases are selectively activated in subjects suffering from nervous system damage as compared to healthy subjects. Breakdown products reflecting protease activation are produced and detection of these different biomarkers of the invention is also diagnostic of the degree of severity and type of nerve damage in a subject.


An in vitro diagnostic (IVD) device is used to detect the presence of and/or severity of neural injuries or neuronal disorders in a subject. The IVD device relies on an immunoassay which identifies biomarkers that are diagnostic of neural injury and/or neuronal disorders in a biological sample, such as whole blood, plasma, serum, and/or cerebrospinal fluid (CSF). An IVD device may measure one or more of several neural specific markers in a biological sample and output the results to a machine readable format, either to a display device or to a storage device internal or external to the IVD.


The present invention relates to an exemplary in vitro diagnostic (IVD) device used to detect the presence of and/or severity of neural injuries or neuronal disorders in a subject. The IVD device relies on an immunoassay which identifies biomarkers that are diagnostic of neural injury and/or neuronal disorders in a biological sample, such as whole blood, plasma, serum, cerebrospinal fluid (CSF). The inventive IVD device may measure one or more of several neural specific markers in a biological sample and output the results to a machine readable format wither to a display device or to a storage device internal or external to the IVD.


Patent
Banyan Biomarkers, Inc. | Date: 2014-03-17

An in vitro diagnostic (IVD) device is used to detect the presence of and/or severity of liver injury in a subject. The IVD device relies on an immunoassay which identifies biomarkers that are diagnostic of liver injury in a biological sample, such as whole blood, plasma, serum. The inventive IVD device may measure one or more of several specific markers in a biological sample and output the results to a machine readable format wither to a display device or to a storage device internal or external to the IVD.


Severe traumatic brain (TBI) injuries are often associated with long-term and disabling consequences. Prognosis and chronic treatment planning following severe TBI remain challenging. The discovery of specific brain biomarkers could create new opportunities for more accurate clinical assessments identifying groups that may experience better outcomes when exposed to an intervention. The present invention provides a method of detection of Microtubule-associated protein-2 (MAP-2), a marker of dendritic damage, in a biological sample of survivors after TBI and evaluates the recovery of the patient, including an improvement in cognitive abilities and function.


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase I | Award Amount: 150.00K | Year: 2015

DESCRIPTION provided by applicant Systemic asphyxia occurs in of births and can lead to hypoxic ischemic encephalopathy HIE Between and of neonates with HIE die or have permanent deficits Although hypothermia is the standard of care for HIE we cannot differentiate patients who respond to hypothermia from non responders The primary goal of this project is to conduct a proof of concept study to validate biomarkers that will rapidl and accurately identify individuals likely to respond to hypothermia or who will die We will measure two serum biomarker levels obtained during the first hours of life with the goal to stratify neonates with HIE into three groups responders to hypothermia non responders at high risk for surviving with neurological and or developmental deficits and neonates who die We will also examine relationships between biomarker levels and brain injury assessed by MRI days after birth Based on data using Ubiquitin C terminal hydrolase L UCH L and glial fibrillary acidic protein GFAP as biomarkers of brain injury in several neurological conditions such as TBI and stroke we will examine the potential of these protein biomarkers to distinguish the three groups Our central hypothesis is that GFAP and UCH L are elevated in neonates with HIE and that changes in these proteins will predict response to hypothermia and death We will determine if analysis of these biomarkers can assist in early and accurate diagnosis of HIE predict responders vs non responders to hypothermia predict brain damage magnitude as assessed by MRI or death Specific Aim a Supplement existing serum sample base of patients with additional samples from no less than patients treated with hypothermia We are currently banking samples from control healthy neonates n and clinical controls n from neonates assessed for jaundice Specific Aim b Complete assay analysis of UCH L and GFAP from all serum samples Specific Aim a Determine whether pre treatment concentrations of the biomarkers UCH L and GFAP can predict the response to hypothermia assessed by volumetric MRI days after birth or death We will also determine the temporal changes of biomarkers during the course of hypothermic treatment Specific Aim b Determine if increased levels of UCH L and GFAP or their ratios measured within hours of birth predict death or the volume of brain injury assesses by volumetric MRI days following birth Commercialization potential Banyan Biomarkerandapos s Inc www banyanbio com has completed enrollment for a FDA sanctioned patient international Pivotal Trial ALERT TBI www clinicaltrials gov to determine the clinical utility of UCH L and GFAP to supplement acute diagnosis of mild and moderate TBI in adults A successful completion of this study will extend the applicability of the biomarkers to HIE afflicted neonates PUBLIC HEALTH RELEVANCE This grant seeks to examine the clinical utility of blood based biomarkers analyzed from samples taken within hours of birth to predict whether neonates having hypoxic ischemic encephalopathy HIE will respond to treatment with hypothermia The study will also examine whether changes on biomarker levels will predict and or reflect the magnitude of brain injury or death Based of Banyan Biomarkers Inc extensive experience in developing biomarkers of brain injury this proposal has significant commercial potential

Loading Banyan Biomarkers, Inc. collaborators
Loading Banyan Biomarkers, Inc. collaborators